Cytodyn Inc (CYDY)

[Saltz]

Buckysherm, you answered your question. Not enough time to be of any significant value in 2017. Look at the time it has taken to get Pro-140 where it is today with two P3's in play and we still have no takers because more data is needed. The value of the indications mentioned are not what BP will be paying for. They want what they perceive as sufficient data to insure FDA Approval. P3's are the acid test and even as effective as Pro-140 appears in the previous trials we are not home yet.

I'm in for 450k shares and my DD tells me Pro-140 is going to shine in both Adjunct and Mono. Nader and people like Dr. Paul Maddon are absolutely convinced on the efficacy and safety. I just really believe this is the real deal and has a very high probability of disrupting the current SOC. At the very least it will be approved for Adjunct. As we all know Mono single agent is the prize and Nader has a pathway that first requires a successful Adjunct P3. I think they believe that is a slam dunk.